Treatment of chronic depression with sertraline or imipramine

Preliminary blinded response rates and high rates of under-treatment in the community

M. B. Keller, W. Harrison, J. A. Fawcett, A. Gelenberg, R. M A Hirschfeld, D. Klein, J. H. Kocsis, J. P. McCullough, A. J. Rush, A. Schatzberg, M. E. Thase

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Despite the prevalence of chronic depression and its associated morbidity, there has been little systematic study of pharmacotherapy for this disorder. In this article, we report a preliminary analysis of the first 12-week phase of a multicenter clinical trial that will eventually include approximately 635 patients in acute, continuation, crossover, and maintenance studies of sertraline, a selective serotonin reuptake inhibitor (SSRI), and imipramine, a tricyclic antidepressant, for the treatment of chronic depression. Of the first 212 patients to enter the study, 168 completed all 12 weeks; of these, 61.3 percent were responders, including 58.9 percent of the 73 patients with chronic major depression and 63.2 percent of the 95 patients with double depression. Only 26.8 percent of the 198 patients for whom such data were available had ever had an adequate trial of an antidepressant medication, defined as 150 mg/day of imipramine or its equivalent taken for st least 4 consecutive weeks. In general, demographic and diagnostic characteristics were more similar than different for patients with chronic major and double depression. However, comorbid generalized anxiety disorder was significantly more common in patients with chronic major depression (11.2% threshold for chronic versus 4.9% threshold for double depression, p=.02). The results of this study provide preliminary evidence of the responsiveness of patients with chronic major or double depression to an SSRI or a tricyclic antidepressant.

Original languageEnglish (US)
Pages (from-to)205-212
Number of pages8
JournalPsychopharmacology Bulletin
Volume31
Issue number2
StatePublished - 1995

Fingerprint

Sertraline
Imipramine
Depression
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Therapeutics
Anxiety Disorders
Cross-Over Studies
Antidepressive Agents
Multicenter Studies
Maintenance
Demography
Clinical Trials
Morbidity
Drug Therapy

Keywords

  • antidepressant agents
  • chronic disease
  • comorbidity
  • depressive disorder
  • psychiatric status rating scales

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Keller, M. B., Harrison, W., Fawcett, J. A., Gelenberg, A., Hirschfeld, R. M. A., Klein, D., ... Thase, M. E. (1995). Treatment of chronic depression with sertraline or imipramine: Preliminary blinded response rates and high rates of under-treatment in the community. Psychopharmacology Bulletin, 31(2), 205-212.

Treatment of chronic depression with sertraline or imipramine : Preliminary blinded response rates and high rates of under-treatment in the community. / Keller, M. B.; Harrison, W.; Fawcett, J. A.; Gelenberg, A.; Hirschfeld, R. M A; Klein, D.; Kocsis, J. H.; McCullough, J. P.; Rush, A. J.; Schatzberg, A.; Thase, M. E.

In: Psychopharmacology Bulletin, Vol. 31, No. 2, 1995, p. 205-212.

Research output: Contribution to journalArticle

Keller, MB, Harrison, W, Fawcett, JA, Gelenberg, A, Hirschfeld, RMA, Klein, D, Kocsis, JH, McCullough, JP, Rush, AJ, Schatzberg, A & Thase, ME 1995, 'Treatment of chronic depression with sertraline or imipramine: Preliminary blinded response rates and high rates of under-treatment in the community', Psychopharmacology Bulletin, vol. 31, no. 2, pp. 205-212.
Keller, M. B. ; Harrison, W. ; Fawcett, J. A. ; Gelenberg, A. ; Hirschfeld, R. M A ; Klein, D. ; Kocsis, J. H. ; McCullough, J. P. ; Rush, A. J. ; Schatzberg, A. ; Thase, M. E. / Treatment of chronic depression with sertraline or imipramine : Preliminary blinded response rates and high rates of under-treatment in the community. In: Psychopharmacology Bulletin. 1995 ; Vol. 31, No. 2. pp. 205-212.
@article{83ffcabff9c64ef48791add5d99508c4,
title = "Treatment of chronic depression with sertraline or imipramine: Preliminary blinded response rates and high rates of under-treatment in the community",
abstract = "Despite the prevalence of chronic depression and its associated morbidity, there has been little systematic study of pharmacotherapy for this disorder. In this article, we report a preliminary analysis of the first 12-week phase of a multicenter clinical trial that will eventually include approximately 635 patients in acute, continuation, crossover, and maintenance studies of sertraline, a selective serotonin reuptake inhibitor (SSRI), and imipramine, a tricyclic antidepressant, for the treatment of chronic depression. Of the first 212 patients to enter the study, 168 completed all 12 weeks; of these, 61.3 percent were responders, including 58.9 percent of the 73 patients with chronic major depression and 63.2 percent of the 95 patients with double depression. Only 26.8 percent of the 198 patients for whom such data were available had ever had an adequate trial of an antidepressant medication, defined as 150 mg/day of imipramine or its equivalent taken for st least 4 consecutive weeks. In general, demographic and diagnostic characteristics were more similar than different for patients with chronic major and double depression. However, comorbid generalized anxiety disorder was significantly more common in patients with chronic major depression (11.2{\%} threshold for chronic versus 4.9{\%} threshold for double depression, p=.02). The results of this study provide preliminary evidence of the responsiveness of patients with chronic major or double depression to an SSRI or a tricyclic antidepressant.",
keywords = "antidepressant agents, chronic disease, comorbidity, depressive disorder, psychiatric status rating scales",
author = "Keller, {M. B.} and W. Harrison and Fawcett, {J. A.} and A. Gelenberg and Hirschfeld, {R. M A} and D. Klein and Kocsis, {J. H.} and McCullough, {J. P.} and Rush, {A. J.} and A. Schatzberg and Thase, {M. E.}",
year = "1995",
language = "English (US)",
volume = "31",
pages = "205--212",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "2",

}

TY - JOUR

T1 - Treatment of chronic depression with sertraline or imipramine

T2 - Preliminary blinded response rates and high rates of under-treatment in the community

AU - Keller, M. B.

AU - Harrison, W.

AU - Fawcett, J. A.

AU - Gelenberg, A.

AU - Hirschfeld, R. M A

AU - Klein, D.

AU - Kocsis, J. H.

AU - McCullough, J. P.

AU - Rush, A. J.

AU - Schatzberg, A.

AU - Thase, M. E.

PY - 1995

Y1 - 1995

N2 - Despite the prevalence of chronic depression and its associated morbidity, there has been little systematic study of pharmacotherapy for this disorder. In this article, we report a preliminary analysis of the first 12-week phase of a multicenter clinical trial that will eventually include approximately 635 patients in acute, continuation, crossover, and maintenance studies of sertraline, a selective serotonin reuptake inhibitor (SSRI), and imipramine, a tricyclic antidepressant, for the treatment of chronic depression. Of the first 212 patients to enter the study, 168 completed all 12 weeks; of these, 61.3 percent were responders, including 58.9 percent of the 73 patients with chronic major depression and 63.2 percent of the 95 patients with double depression. Only 26.8 percent of the 198 patients for whom such data were available had ever had an adequate trial of an antidepressant medication, defined as 150 mg/day of imipramine or its equivalent taken for st least 4 consecutive weeks. In general, demographic and diagnostic characteristics were more similar than different for patients with chronic major and double depression. However, comorbid generalized anxiety disorder was significantly more common in patients with chronic major depression (11.2% threshold for chronic versus 4.9% threshold for double depression, p=.02). The results of this study provide preliminary evidence of the responsiveness of patients with chronic major or double depression to an SSRI or a tricyclic antidepressant.

AB - Despite the prevalence of chronic depression and its associated morbidity, there has been little systematic study of pharmacotherapy for this disorder. In this article, we report a preliminary analysis of the first 12-week phase of a multicenter clinical trial that will eventually include approximately 635 patients in acute, continuation, crossover, and maintenance studies of sertraline, a selective serotonin reuptake inhibitor (SSRI), and imipramine, a tricyclic antidepressant, for the treatment of chronic depression. Of the first 212 patients to enter the study, 168 completed all 12 weeks; of these, 61.3 percent were responders, including 58.9 percent of the 73 patients with chronic major depression and 63.2 percent of the 95 patients with double depression. Only 26.8 percent of the 198 patients for whom such data were available had ever had an adequate trial of an antidepressant medication, defined as 150 mg/day of imipramine or its equivalent taken for st least 4 consecutive weeks. In general, demographic and diagnostic characteristics were more similar than different for patients with chronic major and double depression. However, comorbid generalized anxiety disorder was significantly more common in patients with chronic major depression (11.2% threshold for chronic versus 4.9% threshold for double depression, p=.02). The results of this study provide preliminary evidence of the responsiveness of patients with chronic major or double depression to an SSRI or a tricyclic antidepressant.

KW - antidepressant agents

KW - chronic disease

KW - comorbidity

KW - depressive disorder

KW - psychiatric status rating scales

UR - http://www.scopus.com/inward/record.url?scp=0028872039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028872039&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 205

EP - 212

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 2

ER -